Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| WLK | 8-K | neutral | 4/10 | Westlake completed the previously-announced acquisition of a PVC and VCM production site in Wilhelmshaven, Germany, whic | Jun 15, 2026 |
| NTHI | S-3 | bearish | 5/10 | NeOnc Technologies filed an S-3 registration statement to register 555,554 shares of common stock for resale by selling | Jun 15, 2026 |
| CYTK | CLUSTER | neutral | 2/10 | Two CYTK insiders, including the CEO and EVP of R&D, sold a combined $766K in open-market transactions over a week. The | Jun 15, 2026 |
| CHRS | 8-K | neutral | 3/10 | Coherus Oncology dismissed Ernst & Young as its independent auditor and appointed PricewaterhouseCoopers, effective June | Jun 15, 2026 |
| ONC | CLUSTER | neutral | 2/10 | Five BeOne Medicines insiders, including the CEO, sold a total of $2.0M in shares on June 8, 2026. This represents only | Jun 15, 2026 |
| PURE | 8-K | neutral | 4/10 | PURE Bioscience reported fiscal Q3 2026 revenue of $506,000 (+3% YoY) but net loss widened to $624,000 from $580,000 a y | Jun 15, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | UTHR CEO and CFO sold shares totaling $239K in open-market transactions over a two-day window, alongside routine option | Jun 15, 2026 |
| IMVT | 144 | neutral | 2/10 | Director Atul Pande intends to sell 6,000 shares of Immunovant common stock, valued at approximately $201,720, via a Rul | Jun 15, 2026 |
| VTGN | 8-K | neutral | 4/10 | Vistagen reported fiscal year 2026 financial results with net loss widening to $69.7M and cash at $45.4M, while providin | Jun 15, 2026 |
| VTRS | 8-K | neutral | 3/10 | Viatris entered into an underwriting agreement to issue €650M of 4.250% Senior Notes due 2033, a routine debt capital ma | Jun 15, 2026 |
| INBX | 8-K | bullish | 7/10 | Inhibrx announced FDA acceptance of its BLA for ozekibart (INBRX-109) in unresectable or metastatic conventional chondro | Jun 15, 2026 |
| RYTM | 8-K | bullish | 6/10 | On June 13 and June 15, 2026, Rhythm Pharmaceuticals released positive interim clinical data from its Phase 2 trial of s | Jun 15, 2026 |
| JSPR | DEFA14A | neutral | 2/10 | Jasper Therapeutics filed definitive additional proxy materials (DEFA14A) for its 2026 Annual Meeting scheduled for July | Jun 15, 2026 |
| RYTM | PRESS-RELEASE | bullish | 6/10 | Rhythm Pharmaceuticals presented positive clinical and real-world data at ENDO 2026 for setmelanotide and bivamelagon ac | Jun 15, 2026 |
| PDSB | 8-K | bearish | 7/10 | PDS Biotechnology closed a $6M promissory note financing with Yorkville affiliate YA II PN, Ltd. (10% interest, 12-month | Jun 15, 2026 |
| GWTI | 8-K | neutral | 2/10 | Greenway Technologies entered into a 3-year employment agreement and stock award agreement with CEO Doug Cogan on June 1 | Jun 15, 2026 |
| CXXIF | 6-K | bullish | 7/10 | C21 Investments Inc. announced a definitive arrangement agreement to be acquired by Vireo Growth Inc. in an all-stock tr | Jun 15, 2026 |
| ADTX | 3 | neutral | 2/10 | Bank of America entities filed a Form 3 disclosing beneficial ownership of 57 shares of Aditxt common stock, held indire | Jun 15, 2026 |
| QUCY | PRESS-RELEASE | neutral | 3/10 | Quantum Cyber announced an exclusive worldwide IP license agreement with Project LightShift for quantum photonic array t | Jun 15, 2026 |
| GMAB | 6-K | neutral | 2/10 | Genmab filed a 6-K reporting that Orbis Investment Management Limited reduced its stake from 5.0783% to 4.9917% (3,112,4 | Jun 15, 2026 |
| RKDA | 8-K | bearish | 7/10 | Arcadia Biosciences (RKDA) raised approximately $4M in a private placement of pre-funded warrants and investment options | Jun 15, 2026 |
| XNCR | 144 | neutral | 2/10 | Director Alan Bruce Montgomery filed a Form 144 notice of intent to sell 5,064 shares of Xencor Inc (XNCR) with an estim | Jun 15, 2026 |
| GMAB | 6-K | neutral | 2/10 | Genmab A/S filed its updated Articles of Association via a 6-K on June 15, 2026, reflecting standard corporate governanc | Jun 15, 2026 |
| SLBT | 3 | neutral | 2/10 | Joseph Levinson filed an initial statement of beneficial ownership (Form 3) for SL Science Holding Ltd (SLBT), a Taiwan- | Jun 15, 2026 |
| XNCR | 144 | neutral | 2/10 | Director Richard J. Ranieri filed a Form 144 to sell 5,474 shares of Xencor Inc (XNCR) worth approximately $68,385, acqu | Jun 15, 2026 |
| GSK | 6-K | neutral | 3/10 | GSK filed a routine 6-K disclosing weekly share repurchases under its existing buyback program. The company bought ~1.1M | Jun 15, 2026 |
| BAK | 6-K | neutral | 2/10 | Braskem filed a 6-K announcing the election/re-election of members to its Board advisory committees following the new Sh | Jun 15, 2026 |
| INCR | 6-K | mixed | 5/10 | InterCure completed the first tranche of its Botanico acquisition, issuing 2.47M shares (with another 2.47M to follow), | Jun 15, 2026 |
| CNTX | 8-K | bullish | 7/10 | Context Therapeutics announced positive interim Phase 1a data for CTIM-76, a CLDN6 x CD3 T cell engager, in heavily pret | Jun 15, 2026 |
| ENGN | 8-K | bearish | 6/10 | enGene Therapeutics reported Q2 2026 results with a net loss of $0.43/share, beating consensus of -$0.48, but announced | Jun 15, 2026 |